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Background: The purpose of this study was to compare a weight-adjusted dose of 
  carbidopa-levodopa as treatment adjunctive to occlusion therapy with occlusion therapy alone 
in children and adults with different types of amblyopia.
Methods: This prospective study included 63 patients with amblyopia classified into two 
groups, ie, an occlusion group which included 35 patients who received occlusion therapy 
only and a pharmacological enhancement group which included 28 patients who received oral 
carbidopa-levodopa together with occlusion therapy for 6 weeks.
Results: The mean logarithm of the minimal angle of resolution (logMAR) of the eyes with 
amblyopia was not significantly different in the occlusion group (0.52, 0.52, and 0.51) than 
in the pharmacological enhancement group (0.58, 0.49, and 0.56) at three follow-up visits (at 
months 1, 3, and 12, respectively). There was a highly significant improvement in mean logMAR 
of amblyopic eyes compared with baseline in both occlusion groups (from 0.68 to 0.52, from 
0.68 to 0.52, and from 0.68 to 0.51) and in the pharmacological enhancement group (from 0.81 
to 0.58, from 0.81 to 0.49, and from 0.81 to 0.56) at the month 1, 3, and 12 visits (P = 0.01, 
P = 0.01, and P = 0.001, respectively). The improvement of mean logMAR in the subgroup of 
patients older than 12 years was greater in the pharmacological enhancement group (42.5%) than 
in the occlusion group (30%). The improvement of mean logMAR in the subgroup of patients 
with severe amblyopia was greater in the pharmacological enhancement group (34.3%) than 
in the occlusion group (22%).
Conclusion: Significant improvement was reported in both groups at all follow-up visits over 
1 year. Regardless of the etiology of amblyopia, levodopa-carbidopa may be added to part-time 
occlusion in older patients as a means of increasing the plasticity of the visual cortex. Levodopa 
may add to the effect of occlusion in severe amblyopia and bilateral amblyopia.
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Introduction
Amblyopia describes decreased vision, usually from one eye but occasionally from both 
eyes, despite correction of refractive errors, which cannot be attributed to coexisting eye 
or visual pathway disease. Amblyopia is the most common cause of monocular visual 
loss in children and in young and old children.1 In one study of 250 amblyopes who 
lost vision in their nonamblyopic eye over 2 years from 1997, 25% were left severely 
visually impaired, 25% were unable to drive, and 50% of those in paid employment 
were unable to continue working.2 Occlusion and atropine are accepted modalities of 
treatment. However, many older children and teenagers with amblyopia fail to achieve 
near normal visual acuity. Only 23% (severe amblyopia) to 36% (moderate amblyopia) 
of children aged 7–13 years achieve visual acuity 20/40 or better.1
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Carbidopa-levodopa has been described for the treatment 
of amblyopia since 1993.3 Levodopa is a catecholamine 
precursor used to treat adults with Parkinson’s disease and 
children with dopamine-responsive dystonia. Dopamine 
is a neurotransmitter that does not cross the blood–brain 
barrier. Levodopa is an intermediate in the biosynthesis 
of dopamine that can cross the blood–brain barrier where 
it is converted to dopamine. Carbidopa is a peripheral 
decarboxylase inhibitor that prevents peripheral conversion 
of levodopa to catecholamine metabolites, thus allowing 
more levodopa to cross the blood–brain barrier. This allows 
reduction in the dose of levodopa required for the desired 
effect by about 75%.4 Adults with   Parkinson’s disease can 
tolerate a levodopa dose of up to 30 mg/kg body weight.5 
Levodopa has been also used for many years in children 
to treat dopamine-responsive dystonia. Chronic dosing 
is 4–5 mg/kg in divided doses, although up to 20 mg/kg/
day may be needed.6 Many studies have been performed to 
evaluate the role of levodopa in the treatment of amblyopia. 
Some of these studies used levodopa at a relatively high dose 
(6 mg/kg/day7,8 to 13 mg/kg/day9), but for short durations 
(1 day9 to 1 week7). Other studies used much lower doses of 
1.5 mg/kg/day10–14 for a longer duration (7 weeks), and one 
as yet unpublished randomized trial of levodopa as treatment 
for residual amblyopia used two doses (0.51 mg/kg versus 
0.76 mg/kg, each given three times daily) for 8 weeks.15 
Another study used low doses for shorter durations, ie, 
30 mg/day for 3 weeks.16 Further studies used levodopa 
at a relatively high dose (6–9 mg/kg/day) for a relatively 
short duration (3 weeks)17 or lower doses (1.86 mg/kg/day 
and 2.36 mg/kg/day) for a longer   duration (4 weeks).18 In 
addition, some of these studies7,15,17   compared two different 
doses of levodopa without a control group. Some of these 
trials used levodopa only for residual amblyopia after use 
of other treatments.10,15,19
In mild to moderate amblyopia (visual acuity better than 
0.2) a similar treatment response was seen at 2 hours and 
4 hours of occlusion, and the effect then plateaued with 
additional patching.20 In severe amblyopia (visual acuity 
0.2 or worse), occlusion for 6 hours has been found to be as 
effective as full-time occlusion.21 Some of the previous stud-
ies of levodopa used the drug without occlusion8,11 in some 
patients. Some studies used only 2–3 hours of occlusion7,11,15 
and other studies used full-time occlusion.14,17
The present study used occlusion graded according 
to the severity of amblyopia, and evaluated higher doses 
(6.25–8.3 mg/kg/day) of levodopa for a longer duration 
(6 weeks) in cases not treated previously for amblyopia.
Materials and methods
This prospective interventional study included 63 patients 
aged 3–24 years with amblyopia.
Exclusion criteria were previous amblyopia treatment, 
previous refractive surgery, side effects related to levodopa 
treatment reported as being intolerable by patient or parents, 
and amblyopic eyes with improper or incomplete causal 
treatment.
The subjects comprised 26 males (41.3%) and 37 females 
(58.7%). There were 16 patients (25.4%) aged younger than 
7 years, 28 patients (44.4%) aged 7–12 years, and 19 patients 
(30%) aged 13 years or older. There were 33 patients (52.4%) 
with anisometropic/ametropic amblyopia, seven patients 
(11.1%) with strabismic amblyopia, 20 patients (31.7%) with 
mixed etiology (ametropic-strabismic) amblyopia, and three 
patients (4.8%) with relative amblyopia.
There were 27 patients (42.8%) with mild to moderate 
amblyopia (visual acuity better than 0.2) and 36 patients 
(57.2%) with severe amblyopia (visual acuity 0.2 or worse). 
This classification considered patients with bilateral amblyo-
pia and having one eye affected by severe amblyopia as severe 
cases. There were 15 patients with bilateral amblyopia.
All patients underwent a detailed ophthalmological 
examination, including cycloplegic refraction. Best cor-
rected distance visual acuity was recorded using a Snellen’s 
distance visual acuity chart and converted to a logarithm of 
the minimal angle of resolution (logMAR) equivalent. Any 
significant error of refraction was corrected with glasses or 
contact lens. Any significant angle of deviation was surgi-
cally corrected.
Patients were distributed into two groups. Group 1 included 
35 patients (55.6%) who received occlusion therapy alone 
(occlusion group), and Group 2 included 28 patients (48.4%) 
who received occlusion therapy with levodopa-carbidopa 
(pharmacological enhancement group). Occlusion was 
part-time in both groups, and performed for 2–4 hours in 
patients with moderate amblyopia and for 6 hours in those 
with severe amblyopia.
Carbidopa-levodopa 25/250 (1:10) combination tablets 
(Sinemet®, Merck and Co, Inc, Whitehouse Station, NJ) were 
administered orally in a dose range of 6.25 to 8.3 mg/kg 
(0.5– 2.0 tablets per day). The dose was adjusted according 
to patient weight (Table 1).
All patients were supplied with enough doses for 6 weeks. 
Patients were informed about potential side effects of the drug, 
such as nausea, vomiting, headache, dry mouth,   dizziness, 
fatigue, and sleep disorders. They were also informed about 
the potential benefit and possible treatment   alternatives. 
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Watching for signs of overdose, such as facial muscle 
twitches, sleep disorders, and repeated vomiting, were 
especially reinforced. Phone calls were used to monitor for 
potential side effects of carbidopa-levodopa. If intolerable 
side effects were reported by the patient or parents, the patient 
was excluded from the study.
Visual acuity was followed up at regular intervals for 
12 months. In both groups, any decrease of visual acuity in 
the amblyopic eye necessitated reocclusion of the dominant 
eye to prevent recurrence. Also, any decrease in visual acuity 
in the dominant eye necessitated discontinuation of occlusion 
to prevent reverse amblyopia. Recordings of visual acuity 
and logMAR equivalents were made at months 1, 3, and 12 
after intervention. The data were analyzed using Student’s 
unpaired and paired t-tests and the Chi-square test (χ2).
Results
There were significantly more patients aged younger than 
7 years in the occlusion group. Also, there were significantly 
more patients in the pharmacological enhancement group 
aged older than 12 years. There was no significant difference 
in patient numbers between the groups for patients aged 
7–12 years (Table 2). There was also a higher percentage 
of patients with severe amblyopia in the pharmacological 
enhancement group than in the occlusion group, but the 
difference was not statistically significant (Table 2). There 
was a higher percentage of patients with strabismic amblyo-
pia in the pharmacological enhancement group than in the 
occlusion group, and a higher percentage of amblyopia of 
mixed etiology in the occlusion group. The difference was 
not statistically significant (Table 2). The number of bilateral 
amblyopia cases was higher in the pharmacological enhance-
ment group (11/15). The mean baseline (preintervention) 
logMAR in the amblyopic eye was 0.68 (6/24 equivalent) 
in Group 1 (occlusion group) and 0.81 (6/36 equivalent) in 
Group 2 (pharmacological enhancement group). The differ-
ence was not statistically significant.
The mean baseline logMAR in the dominant eye was 
similar in both groups (Table 3). The mean logMAR at the 
first follow-up visit for the amblyopic eyes was similar in the 
occlusion group at 0.52 (6/18 equivalent) and the pharma-
cological enhancement group at 0.58 (6/24 equivalent). The 
mean logMAR at the first follow-up visit for the dominant 
eye was 0.1 (6/7.5 equivalent) in the occlusion group and 0.06 
(6/6 equivalent) in the pharmacological enhancement group 
(Table 3). The mean logMAR at the second follow-up visit for 
the amblyopic eye was similar between the occlusion group 
at 0.52 (6/18 equivalent) and the pharmacological enhance-
ment group at 0.49 (6/18 equivalent). The mean logMAR for 
the dominant eye at the second follow-up visit was similar 
between the occlusion group 0.07 (6/6 equivalent) and the 
pharmacological enhancement group 0.06 (6/6 equivalent, 
Table 3). The mean logMAR at the third follow-up visit in the 
amblyopic eye was similar in the occlusion group at 0.51 (6/18 
equivalent) and at 0.56 (6/12 to 6/18) in the pharmacological 
enhancement group. The mean logMAR at the third follow-up 
visit was similar (0.07) in both study groups (Table 3).
improvement in amblyopic eyes
There was a highly significant improvement in mean logMAR 
for the amblyopic eyes at the first follow-up visit (month 1) 
compared with baseline in both groups. Also, there was a 
highly significant improvement in mean logMAR at the 
second follow-up visit (month 3) compared with baseline in 
both groups. The same highly significant improvement was 
found in mean logMAR at the third follow-up visit compared 
with baseline in both groups (Table 4).
Table 1 Dose adjustment of levodopa according to patient weight
Levodopa dose Sinemet® Weight (kg) Dose (mg/kg)
125 mg 1/2 tablet/day 15 8.3
125 mg 1/2 tablet/day 20 6.25
250 mg 1 tablet/day 30 8.3
250 mg 1 tablet/day 40 6.25
375 mg 1.5 tablet/day 50 7.5
500 mg 2 tablets/day 60 8.3
Table 2 Comparison between the two study groups with regard 
to age, severity, and causes of amblyopia
Group 1  
(n = 35) 
Occlusion,  
n (%)
Group 2,  
Pharmacological  
enhancement, n = 28 
n (%)
χ2 P value
Age (years)  
8.7
 
0.01* ,7 13 (37.1%) 3 (10.7%)
7–12 16 (45.7%) 12 (42.9%)
.12 6 (17.1%) 13 (46.4%)
Severity  
2.3
 
0.1 Mild to  
moderate  
(VA . 0.2)
18 (51.4%) 9 (32.1%)
Severe  
(VA # 0.2)
17 (48.6%) 19 (67.9%)
Causes  
4.1
 
0.2 Strabismus 2 (5.7%) 5 (17.9%)
Anisometropia 17 (48.6%) 16 (57.1%)
Mixed 14 (40.0%) 6 (21.4%)
Relative 2 (5.7%) 1 (3.6%)
Note: *P , 0.05, statistically significant difference.
Abbreviation: VA, visual acuity.
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improvement in dominant eyes
In the occlusion group, there was no statistically significant 
difference in the dominant eye at the first follow-up visit 
(month 1) for the mean log MAR compared with the baseline 
logMAR (0.12 logMAR and 0.10 logMAR at the first visit). 
In the pharmacological enhancement group, there was a sta-
tistically significant improvement in mean logMAR for the 
dominant eye at the first follow-up visit (month 1) compared 
with baseline (0.1 logMAR at baseline and 0.062 logMAR 
at the first visit, Table 5).
In the occlusion group, there was a statistically significant 
improvement in mean logMAR for the dominant eye at the 
second and third visits compared with baseline (0.11 mean 
logMAR at baseline and 0.07 mean log MAR at the second 
and third visits). In the pharmacological enhancement group, 
there was a significant improvement in mean logMAR for the 
dominant eye at the second and third visits compared with 
the logMAR at baseline (Table 5).
In the subgroup analysis of patients older than 12 years 
in each group, there was an improvement in mean logMAR 
from 0.6 at baseline to 0.42 at final follow-up (30%) in the 
occlusion group. In the pharmacological enhancement group, 
there was a greater improvement from mean baseline log-
MAR of 0.87 to 0.50 at the final follow-up (42.5%; Table 6). 
In the subgroup analysis of patients with severe amblyopia 
in each group, there was an improvement in mean logMAR 
from 1.09 at baseline to 0.85 at the final visit (22%) in the 
occlusion group. In the pharmacological enhancement group, 
there was greater improvement from 1.02 at baseline to 0.67 
at the final visit (34.3%; Table 7). Tolerable side effects of 
levodopa were nausea with or without vomiting, and sleep 
disorders were reported by 4/28 patients (14%).
Discussion
Some previous studies of carbidopa-levodopa have used 
this treatment for a short time (1 week or less),7–9 while 
Table 3 Comparison between the two study groups regarding mean logMAR in both amblyopic and dominant eyes at baseline and at 
month 1, 3, and 12 follow-up visits
Follow-up visit LogMAR Group 1 
Occlusion, n = 35 
Mean ± SD
Group 2 
Pharmacological  
enhancement, n = 28 
Mean ± SD
Paired t P value
Baseline Amblyopic eye 0.68 ± 0.4 0.81 ± 0.4 1 0.3
Dominant eye 0.12 ± 0.1   0.1 ± 0.2 0.2 0.7
First follow-up (month 1) Amblyopic eye 0.52 ± 0.4 0.58 ± 0.4 0.5 0.5
Dominant eye 0.10 ± 0.1 0.06 ± 0.1 1.1 0.2
Second follow-up (month 3) Amblyopic eye 0.52 ± 0.5 0.49 ± 0.4 0.1 0.8
Dominant eye 0.07 ± 0.1 0.06 ± 0.06 0.4 0.6
Third follow-up (month 12) Amblyopic eye 0.51 ± 0.5 0.56 ± 0.5 0.1 0.8
Dominant eye 0.07 ± 0.1 0.07 ± 0.1 0.4 0.7
Abbreviation: logMAR, logarithm of the minimal angle of resolution.
Table 4 Effect of treatment. Comparison between logMAR for amblyopic eyes at baseline and at month 1, 3, and 12 follow-up visits
Log MAR Baseline 
Mean ± SD
Follow-up visit (1) 
1 month  
Mean ± SD
Follow-up visit (2) 
3 months  
Mean ± SD
Follow-up visit (3) 
12 months  
Mean ± SD
Paired t P value
group 1 
(n = 35)
0.68 ± 0.4 0.52 ± 0.4 2.7 0.009**
group 2 
(n = 28)
0.81 ± 0.4 0.58 ± 0.4 5.9 0.000**
group 1 
(n = 35)
0.68 ± 0.4 0.52 ± 0.5 3.9 0.000**
group 2 
(n = 28)
0.81 ± 0.4 0.49 ± 0.4 6.5 0.000**
group 1 
(n = 35)
0.68 ± 0.4 0.51 ± 0.5 3.8 0.000**
group 2 
(n = 28)
0.81 ± 0.4 0.56 ± 0.4 6.6 0.000**
Note: **P , 0.01, highly statistically significant difference.
Abbreviation: logMAR, logarithm of the minimal angle of resolution.
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other studies have used it at low doses.10–15 The present 
study used the drug for a longer duration (6 weeks) and 
at relatively higher doses. Because occlusion of all visual 
input to the better seeing eye represents an established 
treatment approach for amblyopia,20 the present study used 
occlusion in all amblyopic patients as a standard treatment. 
The purpose of this approach was to evaluate the value of 
pharmacological enhancement by levodopa. Preintervention 
characteristics, including mean baseline logMAR in ambly-
opic eyes, degree of amblyopia, and demographic data, 
were not significantly different between the groups. Mean 
logMAR at the three follow-up visits (months 1, 3, and 12) 
was similar in the occlusion group and the pharmacological 
enhancement group. This is contrary to a report by Dadeya 
et al14 who described more improvement of visual acuity 
in a levodopa-occlusion group than in a placebo-occlusion 
group. This may be explained by the different statistical 
methods used in the analysis of these studies. Dadeya 
et al observed eyes with at least two lines of visual acuity 
improvement to be greater at 15/15 (100%) in the levodopa 
group than at 9/15 (60%) in the occlusion group. These 
statistical methods may have led to bias, but are suitable 
for their small sample size.
Further, the present study findings are different from 
those reported by Leguire et al,12 who found that levodopa 
combined with part-time occlusion was more effective 
than levodopa without occlusion in amblyopic eyes. Again, 
this may be due to the small sample size of the study (only 
13 patients) and inclusion of only one age group (7–12 
years), whereas the present study included different age 
groups. Further, there was no detailed description of the 
severity of amblyopia, whereas the present study sub-
group analysis classified patients according to severity of 
amblyopia. A detailed description of the results of our study 
according to preintervention characteristics, including age, 
severity, and type and laterality of amblyopia, can be helpful 
in outcome analysis.
Patient age
Patients aged older than 12 years in both groups showed 
improvement in baseline logMAR, which was found to 
be greater in the pharmacological enhancement group 
(42.5%) than in the occlusion group (30%). Although 
the difference was not significant, it may be explained by 
the fact that addition of levodopa to occlusion is a way to 
expand the patient age range for treatment of amblyopia, 
while keeping the response similar to that in younger 
patients. Mohan et al11 found that patient age had no sig-
nificant effect on mean improvement in visual acuity. The 
levodopa dose was adjusted for body weight in the present 
study (6.25–8.3 mg/kg), and was higher than the dose of 
0.5 mg/kg used by Mohan et al.11
Table 5 Effect of treatment. Comparison between mean logMAR for dominant eye at baseline and at month 1, 3, and 12 follow-up 
visits
LogMAR Baseline 
Mean ± SD
Follow-up visit 1 
(3 months) 
Mean ± SD
Follow-up visits  
2 and 3 
(6 and 12 months)  
Mean ± SD
Paired t P value
group 1 (n = 35) 0.12 ± 0.1   0.10 ± 0.1 1.2 0.2
group 2 (n = 28) 0.10 ± 0.2 0.062 ± 0.1 2.3 0.02*
group 1 (n = 35) 0.11 ± 0.1 0.07 ± 0.1 2.3 0.02*
group 2 (n = 28) 0.11 ± 0.2 0.06 ± 0.1 2.2 0.03*
Note: *P , 0.05, statistically significant.
Abbreviation: logMAR, logarithm of the minimal angle of resolution.
Table 6 Effect of treatment. Comparison between mean baseline 
logMAR and logMAR at the final visit in the subgroup of patients 
older than 12 years in each group
Mean logMAR 
Patients . 12 years
Baseline 
Mean ± SD
Final visit  
Mean ± SD
Occlusion group n = 6 0.60 ± 0.4 0.42 ± 0.5
Pharmacological group n = 13 0.87 ± 0.3 0.50 ± 0.4
Paired t 1.4 0.3
P value 0.2 0.7
Abbreviations: SD, standard deviation; logMAR, logarithm of the minimal angle 
of resolution.
Table 7 Effect of treatment. Comparison between baseline log 
MAR and final visit log MAR in subgroup of patients with severe 
amblyopia
Mean logMAR  
Patients with severe amblyopia
Baseline 
Mean ± SD
Final visit  
Mean ± SD
Occlusion group n = 6 1.09 ± 0.3 0.85 ± 0.4
Pharmacological group n = 13 1.02 ± 0.3 0.67 ± 0.4
Paired t 0.5 1.1
P value 0.5 0.2
Abbreviations: SD, standard deviation; logMAR, logarithm of the minimal angle 
of resolution.
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Further, the similar outcome in the younger and older age 
groups in the present study was different from that reported 
by Dadeya et al,14 who reported that levodopa improved 
visual acuity significantly only in patients younger than 8 
years. This difference may be explained by the smaller sample 
size (only 15 patients in each group) and/or smaller dose of 
levodopa (0.5 mg/kg) in the Dadeya et al14 study than in our 
work. The statistical methods used included the percentage 
of eyes achieving at least two lines of improvement, and 
found them to be 100% in patients younger than 8 years and 
60% in patients older than 8 years. The present study used 
the mean logMAR for group comparison.   Treatment success 
was similarly reported by Scheiman et al for strabismic and 
anisometropic patients who were older than the usual age for 
therapeutic success.22
The effect of levodopa on older amblyopes in the 
  present study can be supported experimentally. Levodopa 
as a catecholamine precursor can affect visual function in 
older children. Depletion of catecholamines by a neurotoxin 
(6-hydroxydopamine) halts the plasticity of the visual cortex 
in young kittens. Plasticity can be re-established by infusion of 
exogenous catecholamines into the brain or by direct electrical 
stimulation of a locus which projects catecholamine fibers 
to the visual cortex.23 Further support of a cortical origin for 
amblyopia is demonstrated by Phillipson et al.24 They found 
dopaminergic innervation from the ventral tegmental area 
to striate cortex laminae I, V , and VI. Also, they found that   
lamina VI sent afferents to lamina IV , and neurons arising 
from lamina IV give rise to the dendritic tree of lamina VI. 
This feedback loop within the cortical laminae is in part con-
trolled by dopaminergic innervation. Further support for the 
re-establishment of cortical plasticity is the significant sponta-
neous improvement in visual acuity of the amblyopic eye a few 
days after loss of vision in the dominant eye in 10% of adult 
amblyopic patients, as reported by Chua and Mitchell.32
Severity of amblyopia
In the present study, a subgroup of patients with severe 
amblyopia in each group showed improvement in baseline 
logMAR. This was found to be greater in the pharmaco-
logical enhancement group (34.3%) than in the occlusion 
group (22%). The difference was not statistically significant. 
Also, the mean preintervention logMAR denoted that visual 
acuity was worse in the pharmacological enhancement 
group. However, the mean logMAR was similar in both 
groups at the follow-up visits, suggesting that addition of 
levodopa to occlusion can lead to a visual outcome of severe 
amblyopia similar to that of mild to moderate amblyopia. 
Mohan et al11 reported that there was no correlation between 
baseline visual acuity and treatment effect. They did not 
conclude advantage for levodopa over occlusion. This can be 
explained by their subgroup distribution. They included the 
levodopa alone group and the levodopa with occlusion group. 
They did not include a subgroup of occlusion alone.
The present study results showing more improvement 
of severe amblyopia in the pharmacological enhancement 
group can be explained by better patient co-operation with 
levodopa-occlusion. This finding is supported by that of 
Awan et al,25 who reported poor compliance with patching 
in patients with poor initial visual acuity.
Types of amblyopia
There was a higher percentage of strabismic amblyopia in 
the pharmacological enhancement group. However, there 
was a higher percentage of mixed etiology amblyopia in the 
occlusion group, comprising a mixture of strabismus and ani-
sometropia, so our study cannot explain a greater response of 
certain types of amblyopia to pharmacological enhancement 
by levodopa. This finding is similar to the results reported by 
Mohan et al,11 who found no significant difference in mean 
improvement of visual acuity among strabismic, ametropic, 
and mixed types of amblyopia. Similarly, Attebo et al26 
reported that anisometropic amblyopia tends to be diagnosed 
later than strabismic amblyopia or when strabismus appears 
(ie, mixed etiology) because the anisometropic child has only 
a mononuclear vision problem that is difficult to detect.
Laterality of amblyopia
Levodopa was significantly more effective in the dominant 
eye at the first follow-up visit. Also, there was a greater 
number of bilateral amblyopia cases in the pharmacological 
enhancement group. However, the mean logMAR in the 
dominant eye was similar in both groups at the second and 
third follow-up visits, being nearly 6/6 equivalent in both 
groups. This means that levodopa adds to the effect of occlu-
sion in bilateral cases, especially in improvement of visual 
acuity in dominant eyes. This may decrease the risk of reverse 
amblyopia in patients with bilateral amblyopia. This is 
similar to the conclusion reached by Wali et al,27 who stated 
that the normal eye in amblyopes is not actually normal and 
exhibits various degrees of visual loss, so is better referred 
to as the dominant eye. The same observation is made by 
Leguire et al,12 who stated that simultaneous use of levodopa 
and occlusion interacts to achieve significant improvement 
in visual function, and to a greater extent than sequential 
combination of levodopa with occlusion alone.
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The results of the present study can be explained by 
the fact that the major metabolite of levodopa is dopamine. 
Dopamine constricts the receptive field size of horizontal 
cells, thus increasing the spatial frequency of the retina. 
Change in the retinal receptive field increases visual acuity 
in both amblyopic and dominant eyes.28 This is further sup-
ported by the finding in Parkinson’s disease of reduced retinal 
function that is improved by levodopa.24 Thus, in amblyopia, 
as in Parkinson’s disease, levodopa improves visual function 
by increasing retinal dopamine levels and decreasing recep-
tive field size. Levodopa probably acts on dopamine receptors 
(D1 and D2) widely present in the retinal pigment epithelium, 
photoreceptors, and amacrine and horizontal cells.28
Demer et al29 have reported reduced glucose metabolism 
in the visual cortex of amblyopes using positron emission 
tomography. Using functional magnetic resonance imag-
ing, Sireteanu et al30 found a normal striate cortex and an 
adversely affected extrastriate cortex. Further, Von Noorden 
and Crawford31 found that layers supplied by amblyopic eyes 
were shrunken in the ipsilateral geniculate body. Because 
the greatest input (80%) to the ipsilateral geniculate body is 
from the visual cortex, changes in the ipsilateral geniculate 
body would be secondary to influences from the cortex 
rather than primary ones. These studies support the role of 
the cortex in amblyopia and therefore a role for levodopa at 
the cortical level.
Carbidopa-levodopa therapy was stopped in the present 
study after 6 weeks. However, the effect of improvement 
was still present until the final follow-up visit at 1 year. This 
effect was maintained in both groups. Further, occlusion was 
maintained in both groups as long as there was a difference 
in visual acuity between the eyes. This may explain the role 
of occlusion in inducing a plateau effect, even in the pharma-
cological enhancement group, and also explains maintenance 
of the treatment effect during 1 year of follow-up. This is 
different from the findings reported by Mohan et al,11 who 
described statistically significant regression of visual   acuity 
in patients aged older than 10 years, but included only 
16 patients in this age group and assessment was acknowl-
edged to be unreliable. Also, details of occlusion duration 
and reuse of occlusion were not mentioned. The sustained 
effect of levodopa seen in this study may be due to a higher 
dose (6.25–8.3 mg/kg) compared with the 0.5 mg/kg dose 
used by Mohan et al.11 The sustained improvement in visual 
function after cessation of treatment in the present study can 
be explained by restoration of cortical plasticity, achieved 
by increasing brain catecholamine levels. However, this 
would predict return of visual acuity to baseline levels after 
  cessation of the drug unless the improvement was maintained 
by occlusion.
Conclusion
Higher weight-adjusted doses of levodopa may represent a 
tool additional to occlusion for expanding both the age limit 
for treatment beyond 12 years and the range of severity of 
amblyopia that can be treated successfully, but in this study 
could not be shown to be more beneficial in certain types 
of amblyopia. Occlusion is the gold standard for treatment 
of amblyopia. Levodopa may be helpful for bilateral cases 
and for avoiding reverse amblyopia. Maintained occlusion 
is helpful to maintain the long-term outcome.
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